Pacifica Partners Inc. Trims Stake in Johnson & Johnson $JNJ

Pacifica Partners Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 42.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 22,310 shares of the company’s stock after selling 16,629 shares during the period. Johnson & Johnson comprises 2.1% of Pacifica Partners Inc.’s holdings, making the stock its 18th largest position. Pacifica Partners Inc.’s holdings in Johnson & Johnson were worth $4,626,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $4,877,174,000. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 3.8% during the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock valued at $4,789,914,000 after purchasing an additional 956,239 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after purchasing an additional 835,146 shares during the period. Legal & General Group Plc grew its stake in Johnson & Johnson by 2.8% in the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock worth $3,606,431,000 after purchasing an additional 532,790 shares during the period. Finally, Amundi raised its holdings in Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company’s stock worth $2,512,719,000 after purchasing an additional 2,163,838 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last three months. 0.16% of the stock is owned by insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 1 intravesical delivery of erdafitinib in non‑muscle invasive bladder cancer reported high (≈89%) response rates and durable complete responses with a favorable safety profile — a meaningful clinical readout that could expand J&J’s oncology opportunity if confirmed in later trials. Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate
• Positive Sentiment: FDA cleared the TECNIS PureSee intraocular lens (extended depth‑of‑focus option) — expands J&J’s cataract/vision portfolio and supports procedure revenue growth in ophthalmology. Device approvals tend to drive steady, low‑volatility revenue additions. Johnson & Johnson Targets Procedure Growth With Bladder Cancer And Vision Advances
• Positive Sentiment: Company is pursuing oncology expansion with new trials and delivery technologies, underscoring management’s focus on growing the oncology franchise over time. This supports longer‑term sales and pipeline value. Johnson And Johnson (NYSE:JNJ) Targets Oncology Growth Through New Trial Russell 1000
• Positive Sentiment: Collaboration/clinical partnering moves (e.g., work with Protagonist) aim to broaden immunology/dermatology and compete with established products like Skyrizi — potential upside if programs advance. Protagonist Partners With Johnson & Johnson To Compete With AbbVie’s Skyrizi
• Neutral Sentiment: Technically, JNJ has traded above its 50‑ and 200‑day moving averages for months, which many investors view as bullish momentum — may support demand absent new negatives. J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
• Neutral Sentiment: Analyst/ broker commentary and ratings pieces are circulating; these can influence intraday flows but don’t change fundamentals unless accompanied by guidance or material news. Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
• Neutral Sentiment: Former J&J oncology executive Craig Tendler moving to TuHURA is being reported; as he is already a former head, immediate operational impact at J&J appears limited. Craig Tendler, M.D., JNJ’s Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience’s VISTA Program in AML and other Blood Related Cancers
• Negative Sentiment: Analyst pieces also flag ongoing patent and legal risks (historical and potential future litigation) that remain a valuation overhang and could spur downside if developments accelerate. J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

Johnson & Johnson Price Performance

JNJ opened at $235.03 on Wednesday. The firm has a market cap of $566.09 billion, a PE ratio of 21.27, a P/E/G ratio of 2.32 and a beta of 0.34. The stock has a 50-day moving average price of $236.15 and a 200-day moving average price of $209.61. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. HSBC lifted their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a report on Tuesday, January 27th. Finally, Barclays raised their target price on shares of Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.